Blog
RSS FeedPosted by Michael Wonder on 17 Jan 2022
Swissmedic grants temporary authorisation to Xevudy for COVID-19 patients
14 January 2022 - Corona medication Xevudy from GSK (sotrovimab) granted temporary authorisation in Switzerland ...
Posted by Michael Wonder on 14 Jan 2022
Celltrion wins conditional nod for Regkirona in Switzerland
14 January 2022 - Celltrion said that Swiss Medic, Switzerland’s drug administration, has temporary authorisation for Regkirona (regdanvimab). ...
Posted by Michael Wonder on 29 Dec 2021
Swiss regulator approves Roche-Regeneron COVID-19 drug
27 December 2021 - The Swiss medicines agency, Swissmedic, has given the green light to the monoclonal antibody cocktail Ronapreve developed ...
Posted by Michael Wonder on 07 Nov 2021
EffRx obtains Swiss marketing authorization for Bronchitol in cystic fibrosis
4 November 2021 - EffRx Pharmaceuticals today announced that Swissmedic has approved Bronchitol (inhaled mannitol) for the treatment of cystic fibrosis ...
Posted by Michael Wonder on 12 Oct 2021
Deciphera announces approval of Qinlock in Switzerland for the treatment of fourth-line gastro-intestinal stromal tumour
12 October 2021 - Seventh approval worldwide for Qinlock and first European approval. ...
Posted by Michael Wonder on 27 Aug 2021
BioCryst announces acceptance of regulatory applications for Orladeyo (berotralstat) by Health Canada and Swissmedic
25 August 2021 - BioCryst Pharmaceuticals today announced that the new drug submission for Orladeyo (berotralstat) has been accepted for ...
Posted by Michael Wonder on 24 Aug 2021
Clovis Oncology announces availability of and reimbursement for Rubraca (rucaparib) tablets for women with relapsed ovarian cancer in Switzerland
24 August 2021 - Rubraca is commercially available in Germany, United Kingdom, Italy, Spain, France, Netherlands, United States of America and ...
Posted by Michael Wonder on 19 Aug 2021
BeiGene announces acceptance by Swissmedic of marketing authorisation application for Brukinsa (zanubrutinib) in Waldenström’s macroglobulinaemia
18 August 2021 - BeiGene announced that Swissmedic has accepted the marketing authorisation application for Brukinsa, a treatment option for adult ...
Posted by Michael Wonder on 16 Jun 2021
Emmaus Life Sciences announces submission of marketing authorisation application to Swissmedic; Ideogen to manage early access program
15 June 2021 - Emmaus Life Sciences anounced today it has received confirmation from the Swiss Agency for Therapeutic Products ...
Posted by Michael Wonder on 06 Jan 2021
MorphoSys and Incyte announce the acceptance of the Swissmedic marketing authorisation application for tafasitamab
5 January 2021 - The Swissmedic marketing authorisation application seeks approval for tafasitamab in combination with lenalidomide for the treatment ...
Posted by Michael Wonder on 21 Dec 2020
Swissmedic approves Buvidal for the treatment of opioid dependence
18 December 2020 - Camurus announced today that the Swiss agency for therapeutic products, Swissmedic, has approved weekly and monthly Buvidal ...
Posted by Michael Wonder on 10 Dec 2020
Switzerland ramps up COVID-19 vaccine order
9 December 2020 - Switzerland has increased its coronavirus vaccine order with Moderna by three million doses. ...
Posted by Michael Wonder on 22 Aug 2020
Swissmedic approval times slow down
20 August 2020 - Swissmedic took 4% longer to process each new application for a new active substance (NA NAS) ...
Posted by Michael Wonder on 20 Aug 2020
Swiss data protection chief pushes back on drug pricing secrecy
20 August 2020 - A proposed change to the new health insurance law that seeks to keep drug prices under lock ...
Posted by Michael Wonder on 13 Aug 2020
Drug prices fall in Switzerland but generics remain expensive
13 August 2020 - Switzerland is narrowing the gap with other European countries when it comes to the cost of medicines. ...